we have produced a chimeric single-chainT cell receptor (TcR) that combines the specific antibody recognition function and TcWCD3 signaling properties within the same polypeptide chain. This hybrid molecule consisted of a single-chain antibody combining site that was connected over a short spacer to the transmembrane and cytoplasmic region of CD31;. When expressed on TcR-or TcRf T cell hybridomas it could mediate recognition of relevent target cells and subsequent production of lymphokines; i. e. it could functionally replace the TcR/CD3 complex. Therefore, the single-chain TcR model presented here represents an interesting and useful means for the creation of T cells with new specificities.
Introduction
TheT cell antigen receptor (TcR) is a multiprotein complex composed of at least six different transmembrane proteins.
The TcR a and fi chains are expressed as covalently linked afi heterodimers which provide the antigen specificity for T cells. While these proteins have large extracellular domains, their cytoplasmic portions contain only a few amino acids. The a and fi chains are noncovalently associated with the invariant subunits CD3y, -6, -E, -5 andor -11 to form TcWCD3 complexes [l] . These associated proteins have large intracellular domains and are thought to couple the process of antigen recognition to the signal transduction pathways of the Tcell [2, 31. We wanted to bypass this complexity by creating a chimeric molecule that would retain both signaling and recognition functions within one polypeptide chain to generate an easily manipulatable system, which would allow us to change the specificity of a T cell at will.
Following several experiments which showed, that the intracellular portion of the CD3c chain would be sufficient to induce activating signals after cross-linking of their artificial extracellular domains [4-61 we constructed a hybrid molecule, which unified the signaling properties of the CD35 chain and the antigen-binding ability of an antibody. For this we used a single-chain (Fv) mAb form [7] derived from TR66, an mAb specific for human C D~E [8] , and grafted it onto a short polypeptide spacer (hinge) from the CD8a chain. This chimeric extracellular domain was then finally fused to the transmembrane and cytoplasmic region of CD3c to form the single-chain TCR ''FvCD3%,: When the construct coding for the single-chain TcR was transfected into TcR-or TcR+ T cell hybridomas, the Since the antigen specificity of our model chimera can easily be changed by replacing its Fv domain by other Fv derived from any antibody, this system could be useful in creating T cells of any desired specificity, bypassing the necessity of MHC restriction.
Materials and methods

Construction of the chimeric FvCD3L;
The vector pHPAPr-1-neo-FvCD31; was designed to express the chimeric FvCD3L construct under the control of the human fi-actin promoter and bears a selectable neomycin marker. For its construction we removed the unique EcoRI restriction site in the plasmid pHPAPr-1-neo [9] by digesting it with EcoRI, blunting its cohesive ends and religating it. The polymerase chain reaction (PCR) was used to amplify a cDNA segment encoding for the cytoplasmic und transmembrane region of the murine CD35 chain and 42 amino acids of the hinge region of murine CD8a (oligonucleotide primers 5451,5452). As a template for this reaction we used the plasmid CDS5 [6] . The primers of this reaction contained a SalI and a HindIII restriction site so that the amplified PCR product could be cloned after digestion with SalI and HindIII into the SalI-Hind111 opened pHfiAPr-1-neo(RI). The resulting plasmid was opened by SalI, blunted and recut with EcoRI to receive the EcoRI-digested PCR-amplified cDNA fragment coding for theVDJ heavy and VJ light chain region of the mAbTR66. As a template for this PCR amplification we used the plasmid FvCD3 Hy3 [lo] and the oligonucleotide primers 5971 and 5979 with the latter containing an EcoRI cloning site.
The sequences of the used oligonucleotide primers are: 
Immunofluorescence
Expression of cell surface proteins was assayed by indirect immunofluorescence. Cell suspensions of 1 x 105 viable cells were stained with 20 p g / d of first-step mAb. After 30 min of incubation the cells were washed and incubated with the second-step FITC-conjugated goat anti-rat Ig (Southern Biotechnologies) at 10 pg/ml. Stained cells were washed and fixed in 1 % formaldehyde prior to cytofluorometric analysis using a FACScan (Becton Dickinson).
dehyde. When the APC A20 was used to present influenza virus hemagglutinin peptide, the A20 cells were irradiated 3 Results and discussion
General strategy
To investigate if the TCR/CD3 multiprotein complex could be replaced functionally by a single-chain chimeric polypeptide, we designed a chimeric gene, which could direct the synthesis of a protein consisting of the cytoplasmic and transmembrane region of mouse CD3<, a 42-amino acid segment of mouse CD8a as extracellular hinge region and the antigen combining site of the mAb TR66 (Fig. 1B) ; TR66 is specific for the human C D~E chain [8] , which was already successfully modified to bispecific single-chain Fv molecules by Traunecker et al. [lo] . The final construction (Fig. 1A) was then transfected by protoplast fusion [20] into the T hybridomas BWa-p-(TcR-) and 14.3d (TcR+) and G418-resistant stable transfectants were isolated and analyzed for expression and function of the chimeric single-chain TcR.
Biochemical characterization of cell surface proteins 3.2 Surface expression and protein characterization
Viable cells (3 x lo7) were washed five times in washing buffer (PBS, 1 m~ MgC12, 0.1 mM CaC12) and then biotinylated for 30min at 4°C in Sulfo-NHS biotin (Pierce, 0.5 m g / d in washing buffer). After another five washes the biotinylated cells were lysed in lysis buffer containing 150 m~ NaCl, 50 m~ Tris, 1 mM PMSF, 10 mM iodoacetamide and 0.5 % NP40 or 1 YO digitonin. The lysate was precleared overnight with protein G-Sepharose (Pharmacia) and the immunoprecipitation was performed for 2 h with 10 pg specific mAb followed by a 1-h incubation with protein G-Sepharose. The precipitate was washed four times in lysis buffer and then boiled in 40 pl of 1.5 x Laemmli sample buffer prior to SDS-PAGE using 12.5 YO or gradient gels.The proteins were transferred from the SDS-PAGE to nitrocellulose which was then blocked in PBS, 0.4% Tween-20 (PBS-T) containing 5 % nonfat dry milk. It was subsequently incubated for 1 h in PBS-T containing 0.08 pg/ml streptavidin-horseradish peroxidase conjugate (Southern Biotechnology). The blot was washed three times for 5 min in PBS-T before addition of the ECL chemoluminescence reagent (Amersham) and the nitrocellulose was exposed to an X-ray film (Kodak) for 30 s to 3 min.
Stimulation of T cell transfectants
In each assay 5 x 10" responder cells were stimulated with different amounts of humanT cells,which were fixed before the experiment by a 30-s treatment with 0.05 YO glutaral-
The immunofluorescence analysis (Fig. 2) shows that the parental hybridomas BWa-p-( Fig. 2A ) and 14.3d (Fig. 2C ) did not stain with the mAb anti-FvCD3, while the surface-labeled 14.3d transfectant with 1 % digitonincontaining lysis buffer, which preserves the TcR/CD3 association. The digitonin lysate of the 14.3 transfectant was either used for precipitation with the anti FvCD3-mAb (Fig. 3, lanes 5 , 6 ) or with F23.1 [15] , and antibody specific for the VPS segment of the TcRP chain (Fig. 3, lanes 7,8) .
The SDS-PAGE-analysis under nonreducing conditions revealed, that the F23.1 precipitation pattern of the untransfected 14.3d and its transfectant were identical: the major protein was the TcRaf3 heterodimer while an additional coprecipitated FvCD3S homodimer on the transfectant could not be detected (Fig. 3, lanes 5, 6) . Vice versa the immunoprecipitation with anti-FvCD3 did not coprecipitate TcR polypeptides from the 14.3d-transfectant (Fig. 3, lane 7 ).
This analysis of the 14.3d transfectant indicated, that the chimeric FvCD31; protein was expressed independently from endogenousTcR/CD3 proteins and that its major form was a homodimer. Therefore, the presence of the endogeneous TcR/CD3 complexes of the 14.3d transfectants should not sterically hinder the function of the FvCD35 polypeptide and vice versa. transfectants of each hybridoma (Fig. 2B,C) showed a surface staining indicating that the FvCD3 determinant was expressed on their surface. In contrast to 14.3d and its transfectants (Fig. 2C,D) , the BWa-P-transfectants (Fig. 2B) as well as the parental BWa-f3-( Fig. 2A) did not express endogenous TcR/CD3 complexes, as monitored with the mouse CD3~-specific mAb 2Cll [14] .
Theoretically, several possible forms of chimeric singlechain TcR could be expressed on the surface of the transfectants: while the BWa-P-transfectants should express FvCD31; independently of endogenous TcR/CD3 complexes, an association could appear in the 14.3 transfectants. FvCD31; could then associate with endogenous TcR/CD3 complexes on the cell surface by charge pairing of its CD31; transmembrane region [21] . Furthermore, this CD35 transmembrane region could potentially permit covalent disulfide linkage between the single-chain FvCD31; and endogenous wild-type CD31; chains, resulting in the formation of CD31;-FvCD31; heterodimers. To investigate which of these was expressed on the surface of our transfectants, we biotinylated the cell surface of these cells, lysed them either in 0.5 % "40 or 1 % digitonin and used the lysates for immunoprecipitations.
The SDS-PAGE analysis of the immunoprecipitations under reducing conditions, followed by a Western blot analysis (Fig. 3, lanes 1,2) , showed that the FvCD31; protein had an apparent molecular weight of 60 OOO on the BW transfectant when the FvCD3-specific mAb was used for precipitation. When analyzed under nonreducing conditions the FvCD31; protein seemed to have a dimeric and to a lesser degree tetrameric form on the BWa-fk transfectant (Fig. 3, lane 4) .
Surprisingly we could only detect homodimers on the surface of the 14.3d transfectant (Fig. 3, lane 7) and no CD3L-FvCD31; heterodimers; these findings suggest that those kinds of heterodimers are either not transported to the cell surface or they are not formed at all.
To detect the eventual associations between FvCD31; and endogenous TcR/CD3 components we lysed the biotin
Functional tests of the FvCD3c chimera
According to the experiments of Irving and Weiss [4] and Romeo and Seed [5] the presence of the intracellular portion of CD35 was sufficient to activate their transfectants when the extracellular domains of their chimeric proteins CDS1; or CD45 were cross-linked by either CD8-specific mAb or gpl2O.We wanted to extend these findings and test if our transfectants would be able to recognize antigen (human C D~E ) through their FvCD3 domain and if this was sufficient to activate the T cell transfectants. 3) and one of its transfectants BWTFl (lanes 2,4) as well as 14.3d (lanes 6, 8) and its transfectant 14.3dTFl (lanes 5, 7) were cell surface biotinylated, lysed in either 0.5 % "40-(lanes 1-4) or 1 % digitonin- (lanes 5-8) containing lysis buffer.The lysates were used for immunoprecipitations with either FvCD3-specific mAb (lanes 1-4, 7, 8) or TCR-specific mAb F23.1 (lanes 5 , 6 ) . 
PEPTIDE CONCENTRATION (FM) JURKAT
As stimulators we used Jurkat (Fig. 4B, D) , a human CD3+ T cell lymphoma and GC13 (Fig. 4A ), a humanT cell clone (A. Lanzavecchia, unpublished data). Both stimulators were fixed before the functional assays in order to make sure, that they could not be a source of lymphokine production (data not shown). Fig. 4A and B shows the results of the stimulation of BWa-P-and two of the BW transfectants. While the untransfected parental hybridoma was apparently neither activated by the stimulator cells GC13 (Fig. 4A ), nor Jurkat (Fig. 4B) , the two transfectants produced IL-2 ( Fig. 4A, B) and IL-3 (data not shown) in a manner which was dependent on the number of each of the two types of stimulator cells. Furthermore, this stimulation could be inhibited specifically by TR66 (data not shown), the CD3&-specific mAb [8] from which the FvCD3 domain of our chimeric TcR was derived. We tested eight BW transfectants in total and all showed similar stimulation patterns to those showed in Fig. 4 .
To compare the efficiency of IL-2 and IL-3 production after stimulation over the chimeric single-chain receptor with conventional MHC-restricted stimulation with endogenous TcR/CD3 complexes we set up the following experiments: 14.3d and two of its FvCD35 transfectants were tested for IL-3 (Fig. 4C, D) and IL-2 (data not shown) production during stimulation with APC (NO) and different amounts of antigenic peptide (Fig. 4C) or fixed human CD3+ Jurkat cells (Fig. 4D) , respectively. While every tested cell was stimulated in a similarly efficient way by peptide plus A20 (Fig. 4C ), only the transfectants were able to produce IL-3 ( Fig. 4D ) and IL-2 (data not shown) during stimulation by fixed Jurkat cells. Both kinds of assay showed that the production of lymphokines was either dependent on peptide concentration or on the number of stimulator cells, and indicated that the additional anti-human CD3 specificity on the 14.3d transfectants is caused by the expression of the single-chain TcR. A comparison of the stimulation efficien- cies through endogeneous TcR (Fig. 4C ) and FvCD35 single-chain TcR (Fig. 4D) shows that both signaling machineries seem to be similarly efficient in inducing lymphokine production in the same cell. While the peptide antigen presented by A20 is recognized in an MHC-restricted way, the CD3 recognition through FvCD35 resembles an antibody-antigen interaction where no restricting MHC is needed.
Concluding remarks
Here we have demonstrated that the biological activities of helper T cell hybridomas can be directed by a single polypeptide chain that is able to recognize antigen and to transduce activating signals into the cell, which result in the production of biologically active lymphokines, in manners indistinguishable from normal antigen-specific stimulation.
The anti-human CD3 specificity used in our experiments can be easily exchanged with Fv, of other desired specificities derived from any existing mAb. Therefore, the singlechain TcR model presented here represents an interesting and useful means for the creation of Tcells with every desired specificity at will. 
